Immediate changes in lung compliance following natural surfactant administration in premature infants with respiratory distress syndrome: A controlled trial

被引：13

作者：

Attar M.A. ^{[1
,3
]}

Becker M.A. ^{[2
]}

Dechert R.E. ^{[2
]}

Donn S.M. ^{[1
]}

机构：

[1] Dept. of Pediatrics/Communic. Dis., University of Michigan, Ann Arbor, MI

[2] Dept. of Critical Care Support Serv., University of Michigan Health System, Ann Arbor, MI

[3] Mott Hospital, Ann Arbor, MI 48109-0254

来源：

Journal of Perinatology | 2004年 / 24卷 / 10期

关键词：

D O I：

10.1038/sj.jp.7211160

中图分类号：

学科分类号：

摘要：

Objective: To compare immediate changes in lung compliance following the administration of two commercially available natural surfactants. Method: We conducted a prospective, randomized study of 40 preterm infants with respiratory distress syndrome requiring surfactant. Infants received either Infasurf® or Survanta®. The primary outcome measure was the change in compliance assessed by bedside pulmonary monitoring. Results: There were no significant changes in dynamic lung compliance within or between the two groups 1 hour after surfactant administration. However, infants given Survanta required more doses per patient (4 vs 2, p = 0.05) and were more likely to require > 2 doses (57 vs 26%, p = 0.05). Infants requiring > 1 dose of surfactant had a greater change in airway pressure and improved oxygenation just before the second dose when treated with Infasurf. Conclusions: We found no significant difference in acute changes in lung compliance. However, treatment with infasurf seems to be more long lasting than Survanta. © 2004 Nature Publishing Group. All rights reserved.

引用

页码：626 / 630

页数：4

共 15 条

[1]

Surfactant replacement therapy for respiratory distress syndrome, Pediatrics, 103, pp. 684-685, (1999)

[2]

Notter R.H., Wang Z., Egan E.A., Holm B.A., Component-specific surface and physiological activity in bovine-derived lung surfactants, Chem. Phys. Lipids, 114, pp. 21-34, (2002)

[3]

Mizuno K., Ikegami M., Chen C.M., Ueda T., Jobe A.H., Surfactant protein-B supplementation improves in vivo function of a modified natural surfactant, Pediatr. Res., 37, pp. 271-276, (1995)

[4]

Cummings J.J., Holm B.A., Hudak M.L., Hudak B.B., Ferguson W.H., Egan E.A., A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterm lambs, Am. Rev. Respir. Dis., 145, pp. 999-1004, (1992)

[5]

Bloom B.T., Kattwinkel J., Hall R.T., Et al., Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome, Pediatrics, 100, pp. 31-38, (1997)

[6]

Attar M.A., Donn S.M., Mechanisms of ventilator-induced lung injury in premature infants, Semin. Neonatol., 7, pp. 353-360, (2002)

[7]

Ikegami M., Agata Y., Elkady T., Hallman M., Berry D., Jobe A., Comparison of four surfactants: In vitro surface properties and responses of preterm lambs to treatment at birth, Pediatrics, 79, pp. 38-46, (1987)

[8]

Bhutani V.K., Abbasi S., Long W.A., Gerdes J.S., Pulmonary mechanics and energetics in preterm infants who had respiratory distress syndrome treated with synthetic surfactant, J. Pediatr., 120, (1992)

[9]

Bhat R., Dziedzic K., Bhutani V.K., Vidyasagar D., Effect of single dose surfactant on pulmonary function, Crit. Care Med., 18, pp. 590-595, (1990)

[10]

Couser R.J., Ferrara T.B., Ebert J., Hoekstra R.E., Fangman J.J., Effects of exogenous surfactant therapy on dynamic compliance during mechanical breathing in preterm infants with hyaline membrane disease, J. Pediatr., 116, pp. 119-124, (1990)

← 1 2 →